Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Fresenius Medical Care First Quarter 2025 Earnings: EPS: €0.52 (vs €0.24 in 1Q 2024)

Fresenius Medical Care (ETR:FME) First Quarter 2025 Results Key Financial Results Revenue: €4.88b (up 3.3% from 1Q 2024). Net income: €151.0m (up 113% from 1Q 2024). Profit margin: 3.1% (up from 1.5% in 1Q 2024). The increase in margin was driven by higher revenue. …

EODHD | 07 May 2025

Adyen N.V.'s (AMS:ADYEN) top owners are retail investors with 50% stake, while 46% is held by institutions

Key Insights Significant control over Adyen by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders own 40% of the company Institutional ownership in Adyen is 46% AI is about to change healthcare. …

EODHD | 07 May 2025

Q1 2025 GlobalFoundries Inc Earnings Call

Participants Sam Franklin; Senior Vice President of Business Finance & Operations; GlobalFoundries Inc Tim Breen; Chief Executive Officer; GlobalFoundries Inc Niels Anderskouv; President, Chief Operating Officer; GlobalFoundries Inc John Hollister; Chief Financial Officer; GlobalFoundries Inc Mark Lipacis; Analyst; Evercore ISI CJ Muse; Analyst; Cantor …

EODHD | 07 May 2025

Q1 2025 Marathon Petroleum Corp Earnings Call

Participants Kristina Kazarian; Vice President - Finance and Investor Relations; Marathon Petroleum Corp Maryann Mannen; President, Chief Executive Officer; Marathon Petroleum Corp John Quaid; Chief Financial Officer, Executive Vice President; Marathon Petroleum Corp Rick Hessling; Chief Commercial Officer; Marathon Petroleum Corp James Wilkins; Senior …

EODHD | 07 May 2025

Related-Party Transactions Reporting

MADRID, May 07, 2025--(BUSINESS WIRE)-- Borja Acha Besga Secretary of the Board of Directors Madrid, 6 May 2025 Pursuant to Article 227 of the Spanish Securities Market Act, Endesa, S.A. hereby reports the following relevant information: Related-Party Transactions Reporting Endesa reports related-party transactions entered …

EODHD | 07 May 2025

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

Ipsen Pharma Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatment IQIRVO dual PPARα/δ activation impacts inflammation and fibrosis PPARα activation linked to fatigue improvement …

EODHD | 07 May 2025

Cybernet and Nokia redefine Pakistan’s network landscape with 1.2T-per-lambda backbone

Nokia Oyj Press Release Cybernet and Nokia redefine Pakistan’s network landscape with 1.2T-per-lambda backbone Cybernet has selected Nokia’s innovative 1830 Global Express (GX) platform with integrated optical line system capabilities and ICE7 coherent optics. Cybernet’s new network will provide connectivity services to over 25 …

EODHD | 07 May 2025

Wolters Kluwer First-Quarter 2025 Trading Update

Wolters Kluwer N.V. Wolters Kluwer First-Quarter 2025 Trading Update Alphen aan den Rijn, May 7, 2025 – Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its first-quarter 2025 trading update. Highlights Full-year 2025 guidance reiterated. First-quarter revenues up …

EODHD | 07 May 2025

Q1 2025 MPLX LP Earnings Call

Participants Kristina Kazarian; Vice President - Finance and Investor Relations of MPLX GP LLC; MPLX LP Maryann Mannen; President and Chief Executive Officer; MPLX LP C. Kristopher Hagedorn; Chief Financial Officer, Executive Vice President, Director of MPLX GP; MPLX LP Gregory Floerke; Chief Operating …

EODHD | 07 May 2025

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies. …

EODHD | 07 May 2025
Support

Hi! How can we help you today?

Loading…